438452-29-0

Basic information

• Product Name: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(4-bromophenyl)sulfonyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4S)-
• CAS NO: 438452-29-0
• Molecular Formula: C17H22BrNO7S
• Molecular Weight: 464.334
• Mol File: 438452-29-0.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(4-bromophenyl)sulfonyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(4-bromophenyl)sulfonyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4S)-(438452-29-0)
• EPA Substance Registry System: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(4-bromophenyl)sulfonyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4S)-(438452-29-0)

Safety Data

• Hazardous Substances Data: 438452-29-0(Hazardous Substances Data)

Usage

Pyrrolidine Core

The central structure of the compound, which is a five-membered ring containing four carbon atoms and one nitrogen atom.

Carboxylic Acid Groups

The compound contains two carboxylic acid groups (-COOH) attached to the pyrrolidine core.

Ester Groups

The carboxylic acid groups are esterified, with one ester group being a 1-(1,1-dimethylethyl) and the other being a methyl group (-CH3).

Bromophenylsulfonyl Moiety

A 4-bromophenylsulfonyl group (-C6H4Br-SO2-) is attached to the pyrrolidine core through an oxygen atom.

Chiral Molecule

The compound is chiral, meaning it has a non-superimposable mirror image.

Asymmetric Carbon Centers

The compound has two asymmetric carbon centers, which contribute to its chirality.

Stereochemistry

The stereochemistry of the compound is (2S,4S)-, indicating the specific arrangement of the atoms around the asymmetric carbon centers.

Potential Applications

The unique structure and properties of the compound may have applications in pharmaceuticals, agrochemicals, or materials science due to its potential for specific interactions with biological systems.

Complex Structure

The compound's complex structure, with multiple functional groups and a chiral center, may contribute to its potential for specific interactions and applications.

Upstream product

• 138-36-3 p-bromobenzene sulfonic acid 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 87250-97-3 2’-methyl-2’-propanyl (1S,4S)-3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylate 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 

Downstream Products

• 367258-59-1 4-(4-bromobenzenesulfonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 1206524-79-9 1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate 
• 921790-38-7 C₂₄H₃₃BrN₂O₈S 
• 1026208-17-2 1-tert-butyl 2-methyl (2S,4R)-4-(1-bromo-naphthalen-2-yloxy)-pyrrolidine-1,2-dicarboxylate 
• 1000063-82-0 1-tert-butyl 2-methyl (2S,4R)-4-[(6-bromo-7-methoxy-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 914835-38-4 1-t-butyl 2-methyl (2S,4R)-4-[(6-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 1020094-40-9 1-t-butyl 2-methyl (2S,4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 
• 367260-69-3 (2S,4R)-1-{(S)-2-Cyclohexyl-2-[2-(3-hydroxy-phenyl)-acetylamino]-acetyl}-4-(3-hydroxy-propylsulfanyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 367258-60-4 12-cyclohexyl-11,14-dioxo-2-oxa-6-thia-10,13-diazatricyclo[14.3.1.1^7,10]henicosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-9-carboxylic acid methyl ester 
• 367259-61-8 methyl (2S,4R)-1-[(2S)-2-cyclohexyl-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxoethyl]-4-[(3-hydroxypropyl)thio]-2-pyrrolidinecarboxylate 
• 1001155-58-3 C₁₂H₁₄BrNO₅S 
• 1369482-19-8 1-tert-butyl 2-methyl (2S,4R)-4-{[4-(benzyloxy)-3-(prop-2-en-1-yl)quinolin-2-yl]oxy}pyrrolidine-1,2-dicarboxylate 
• 914835-77-1 methyl-N-[(hept-6-enyloxy)carbonyl]-L-norleucyl-(4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]-L-prolinate 
• 914836-16-1 methyl (2R,4S,7S)-7-butyl-6,9-dioxo-22-phenyl-3,4,6,7,8,9,12,13,14,15,16,17-dodecahydro-2H,11H-18,20-ethanediylidene-2,5-methanopyrido[4,3-κ][1,10,3,6]dioxadiazacyclohenicosine-4-carboxylate 

Relevant articles and documents

THERAPEUTIC COMPOUNDS

no abstract published

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

HCV NS3 PROTEASE INHIBITORS

The present invention relates to macro-cyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections